Generic name:paliperidone palmitate
Dosage form: extended-release injectable suspension
Drug class:Atypical antipsychotics
What is Invega Hafyera?
Invega Hafyera is a prescription medicine given by injection by a healthcare provider 1 time every 6 months and used for the treatment of schizophrenia in adults who have been adequately treated with either:
- A 1 time each month paliperidone palmitate extended-release injectable suspension for at least 4 months.
- A 1 time every 3 months paliperidone palmitate extended-release injectable suspension for at least 3 months.
It is not known if this medicine is safe and effective in children under 18 years of age.
Important information
Invega Hafyera may cause serious side effects, including:
- Increased risk of death in elderly people with dementia-related psychosis. Invega Hafyera increases the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). Invega Hafyera is not for the treatment of people with dementia-related psychosis.
Who should not receive Invega Hafyera?
You should not receive Invega Hafyera if you are allergic to paliperidone palmitate, risperidone, or any of the ingredients. See the end of this page for a complete list of ingredients.
Before receiving Invega Hafyera
Before you start treatment, tell your healthcare provider about all your medical conditions, including if you:
- have had Neuroleptic Malignant Syndrome (NMS)
- have or have had heart problems, including a heart attack, heart failure, abnormal heart rhythm, or long QT syndrome
- have or have had low levels of potassium or magnesium in your blood
- have or have had uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskine...
